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Insulin-like growth factor-binding protein
3 (IGFBP3) is the major carrier of cir-
culating IGF-I and IGF-II. In complexes
with ALS, IGFBP3 binds IGFs with high
affinity and has a pivotal role in modu-
lating IGFs biological effects by limiting
their bioavailability. These ternary com-
plexes are stabilized by IGF-I and ALS,
both of which are regulated by the pitu-
itary growth hormone. At the tissue level,
however, IGFBP3 is subjected to lim-
ited proteolysis by several enzymes, which
increase the local IGF bioavailability (1).
Besides these “IGF-dependent” IGFBP3
effects, which require a functional IGF-IR,
several recent studies have provided con-
vincing evidence that IGFBP3 also elicits
significant biological effects in an IGF-
independent manner. Indeed, by binding a
variety of other molecular partners, located
both on cell membrane and in the nucleus,
IGFBP3 may modulate cell growth, sur-
vival, and transformation (2, 3). Because
of these complex activities, IGFBP3 has
been considered both a “gatekeeper,” by
halting cell proliferation and promoting
apoptosis in response to DNA damage,
and a “caretaker,” by contributing to DNA
repair (2).
Studies focusing on the pro-apoptotic
and anti-proliferative actions of IGFBP3
have raised hope that these effects could
exploited in cancer therapy, but overall
conclusions have remained uncertain (3–
5). Even very recent in vivo studies have
reached discrepant conclusions. By cross-
ing mice with a genetic deletion of IGFBP3
with mice expressing human Myc in the
prostate, Metha et al. provided in vivo evi-
dence of a role for IGFBP3 as a metastasis
suppression gene (6). Accordingly, methy-
lation of the IGFBP3 gene and low IGFBP3
expression occur frequently in aggressive
colorectal cancer and are associated with
poor response to adjuvant chemother-
apy (7). In contrast, in esophageal squa-
mous cell carcinoma, IGFBP3, which is
induced by hypoxia, mediates the induc-
tion of CD44H cells by suppressing reactive
oxygen species (ROS) (8).
Given the context-dependent, multi-
modal effects of unliganded IGFBP3,
mechanistic studies in well-defined can-
cer cells are therefore needed. In this
respect, the study by Perks et al. (9) is a
good step in the right direction. In this
study, using Hs578T human breast can-
cer cells, the authors have dissected a sig-
naling cascade activated by IGFBP3, shed-
ding new light on IGF-independent, com-
plex effects of IGFBP3 on apoptosis. As
previously described, this cascade is ini-
tiated at the membrane level by IGFBP3
binding to caveolin-1 (Cav-1) (10) at the
level of Cav-1 scaffolding domain, which
also binds and inactivates protein kinase A
(PKA) (11). Now, the authors show that,
upon binding to Cav-1, IGFBP3 induces
Hs578T cell apoptosis by preventing PKA
inactivation. Indeed, the PKA inhibitor
KT5720 was able to revert IGFBP3-induced
apoptosis. To better elucidate this path-
way, the Authors investigated a possible
role of Rho in this pathway. The effects of
Rho are regulated by phosphorylation by
a specific serine/threonine kinase (ROCK).
Notably, the inhibition of ROCK not only
blocked the apoptotic effect of IGFBP3, but
enabled IGFBP3 to act as a survival fac-
tor, confirming an important role for Rho.
Using ROCK inhibitors, it was possible to
establish that Rho is downstream of the
Cav-1/PKA complex. Previously, the same
authors had shown that IGFBP3 binds
also to beta 1 integrin (10), which now
may be considered, together with Cav-1,
upstream to the PKA/ROCK/Rho path-
way. To add complexity to this model,
the authors also showed that this pathway
affects the so-called phospholipid rheo-
stat, which regulates the balance between
the pro-apoptotic ceramide and the pro-
survival sphingosine-1-phosphate (S1P).
In fact, Rho was found to positively regulate
ceramide production, which in turn was
involved in MAPK activation and apopto-
sis. Indeed, ceramide production is essen-
tial to the apoptotic effect of IGFBP3 along
this pathway. However, S1P is enhanced
by various growth factors including EGF,
IGF-1, and insulin, which activate the S1P
kinase, SphK1 (12). IGFBP3 itself may
stimulate SphK1 and favor S1P synthe-
sis, which in turn may transactivate EGFR
and IGF-IR (13, 14). Therefore, in con-
ditions in which ceramide synthesis is
impaired, IGFBP3 may shift the ceramide
to S1P balance in favor of S1P and induce
survival. This paper of Perks et al. has
the merit of having dissected a major
pathway activated by unliganded IGFBP3,
which may induce both pro-apoptotic and
pro-survival effects in a context-specific
manner.
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Several questions still remain open.
Firstly, the context-specific variables that
affect the balance between these two oppo-
site effects are still largely unknown. The
extracellular matrix composition may cer-
tainly be a variable through the involve-
ment of integrins. Indeed, the pro-
apoptotic effect of IGFBP3 could be
reversed by disrupting integrin receptor
complexes (10). The expression level of
Cav-1 in cancer cells might also be a vari-
able. It should be mentioned that of Cav-1
is mostly overexpressed during neoplastic
progression, and that its role in cancer biol-
ogy appears to be multidimensional, as it
may promote tumorigenesis and metasta-
sis, especially in most advanced cancers,
while behaving as an anti-oncogene in
other contexts (15). Whether tumor stage
may also influence IGFBP3 action is poorly
understood.
Secondly, cancer associated fibroblasts
(CAFs) may also express dysregulated Cav-
1 and IGF system components. Interest-
ingly, elevated IGFBP3 has been shown
to play a crucial role in fibroblast-to-
myofibroblast differentiation in high-grade
prostate cancer (16). Moreover, loss of Cav-
1 in CAFs seems to be a marker of oxidative
stress and hypoxia and, in breast cancer, is
associated with poor clinical outcome (17).
One may wonder how Cav-1 and IGFBP3
interact in CAFs.
A third question to be answered is how
the tumor microenvironment may influ-
ence IGFBP3 expression, and how the
effects of IGFBP3 in CAFs and epithelial
cells cooperate.
Finally, the interplay between IGF-
dependent and IGF-independent effects
of IGFBP3 is difficult to address, and is
likely to be context-dependent. Although
it might be reasonable to expect that a
tumor addicted to IGF-IR/IGFs or IR-
A/IGF-2 circuits may favorably respond
to IGF-blocking activity of IGFBP3, it
should be considered that high levels of
IGFs and IGFBP3 may switch the bal-
ance of the phospholipid rheostat in
favor of SP1 by activating SphK1. In
this context, the concomitant inhibition
of SphK1 should perhaps be taken into
consideration.
Overall, it appears that understanding
the diverse abilities of IGFBP3 is certainly
not straightforward, and more mechanistic
studies, possibly on breast cancer stem cells,
are needed to establish whether IGFBP3
could be exploited in breast cancer therapy.
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